Insulin Resistance as the Central Pathophysiological Driver of PCOS

Insulin resistance — present in 50–80% of women with PCOS — is both a driver and amplifier of hyperandrogenemia and reproductive dysfunction, making it the dominant axis across more than 40 retrieved records spanning basic science, randomized controlled trials, and systematic reviews. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling cascade sits at the molecular center of this dysfunction, with defective signal transduction directly linked to anovulation, androgen hypersecretion from theca cells, and impaired folliculogenesis.

At the molecular level, insulin receptor substrate proteins (IRS-1 and IRS-2), the insulin receptor gene (INSR), and PPARγ (peroxisome proliferator-activated receptor gamma) are identified as key genetic and protein targets. Research from the National Institute for Research in Reproductive Health in Mumbai specifically implicates the IRS-1 Gly972Arg polymorphism and INSR variants as genetic susceptibility factors. Hyperandrogenism arises as a consequence of insulin-driven upregulation of LH-stimulated theca cell androgen biosynthesis via CYP17A1 and CYP11A1 enzymes — a mechanism documented by the University of Silesia in Katowice alongside elevated 3β-HSD type II activity.

The gonadotropin axis — specifically elevated LH secretion and an elevated LH/FSH ratio — is confirmed across multiple records as a hallmark of PCOS pathophysiology, with anti-Müllerian hormone (AMH) serving as both a biomarker of follicular arrest severity and a pharmacodynamic endpoint for insulin sensitizer trials. According to WHO, PCOS is recognised globally as a leading cause of female infertility, underscoring the public health urgency of pipeline diversification.

Two records from Shanghai Jiao Tong University’s Renji Hospital identify serum amyloid A1 (SAA1) as an ovarian granulosa cell-expressed inflammatory mediator capable of inducing insulin resistance in a self-amplifying loop via NF-κB-related pathways — with SAA1 levels elevated in PCOS follicular fluid and correlating with insulin resistance status. This positions SAA1 as both a candidate biomarker and a potential therapeutic target with no patent filings yet identified in the dataset, representing a white space for IP development.

Inositol Therapeutics: Clinical Evidence, Dosing Science, and a Paradoxical Safety Signal

Inositol-based interventions are the most extensively represented therapeutic modality in the PCOS literature dataset, with more than 20 retrieved records addressing myo-inositol (MI) and D-chiro-inositol (DCI) directly. Both function as insulin-sensitizing second messengers: DCI-phosphoglycan (DCI-IPG) activates pyruvate dehydrogenase phosphatase governing glucose oxidation, while MI-phosphoglycan (MI-IPG) modulates adenylate cyclase. In phosphoinositide form, they participate in PI3K-dependent insulin signal transduction within granulosa cells.

The Bulgarian systematic review from Alexandrovska University Hospital identified 47 clinical trials — including 35 RCTs — in a PubMed search through September 2020, confirming improvement in ovarian function, hyperandrogenism, and metabolic parameters with inositol treatment. An Indian multi-center observational study across 50 centers (n=283) showed that an MI/DCI combination at 550/150 mg reduced weight in 69.61% of patients and improved LH/FSH ratio and HOMA-IR. A three-arm Indian RCT (n=90, 24 weeks) reported combined metformin plus MI achieving a 93.33% reduction in polycystic ovarian morphology, versus 80% with MI alone and 50% with metformin alone.

“High-dose D-chiro-inositol alone — at doses corresponding to approximately 1,200 mg/day in humans — paradoxically increased serum testosterone and reduced aromatase expression, inducing a PCOS-like phenotype in mouse ovaries.”

Combination strategies extend beyond the MI:DCI ratio. Two records from the Universities of Pisa and Modena document MI combined with alpha-lipoic acid (ALA, 400–800 mg/day with 1000–2000 mg/day MI), demonstrating synergistic improvement in menstrual cyclicity (71.2%), HOMA-IR, and insulin response — with the combination product Sinopol (Laborest) specifically identified. Researchers at Magna Graecia University in Catanzaro document inositol combined with N-acetylcysteine and folic acid (Ovaric HP) as effective in improving ovulation rate and menstrual regularity both in patients with and without insulin resistance, suggesting utility beyond the IR-positive subset.

Established Insulin Sensitizers: Metformin’s Mechanisms and the TZD Evidence Base

Metformin remains the most clinically established pharmacological reference comparator in the PCOS literature, appearing in direct head-to-head comparisons with inositols, thiazolidinediones, GLP-1 agonists, berberine, and N-acetylcysteine. Its primary mechanism in PCOS operates through AMPK activation, suppression of hepatic gluconeogenesis, and downstream reduction of hyperinsulinemia and androgen levels. Research from St. George’s University of London additionally documents metformin inhibition of the FSH/cAMP/PKA pathway and aromatase (CYP19A1) expression in human granulosa cells — with implications for its variable ovulatory effects.

A Seoul National University study (n=123) tracked hormonal and metabolic response to sequential metformin-to-pioglitazone protocols, reporting 45.7% menstrual cycle improvement at 3 months with metformin. Metformin pharmacogenomics are noted in a retrieved record from National Cheng Kung University in Taiwan, identifying OCT1 transporter polymorphisms (rs683369, rs628031) as potential modulators of metformin response. Additional mechanistic evidence from Heilongjiang University of Chinese Medicine identifies metformin-mediated regulation of uterine progesterone receptor (PGR) isoforms A and B and Fkbp52/Ncoa2 as relevant to endometrial implantation failure in PCOS.

Thiazolidinediones (TZDs) — pioglitazone and rosiglitazone — act as PPARγ full agonists, improving insulin sensitivity in skeletal muscle, adipose tissue, and ovarian granulosa cells. A microarray study from the University of Southern Denmark (n=10 obese PCOS women, euglycemic-hyperinsulinemic clamp) documented that pioglitazone 30 mg/day for 16 weeks enhanced mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle. According to research published via Nature-affiliated journals, PPARγ Ser112 and Ser273 phosphorylation states determine the balance between pro-adipocytic and insulin-sensitizing transcriptional activities — with full agonism at Ser273 providing insulin sensitization and full agonism at Ser112 promoting adipogenesis and bone loss.

Poxel SA (Lyon) describes PXL065 — deuterium-stabilized (R)-pioglitazone — as a modified pioglitazone stereoisomer retaining PPARγ Ser273 dephosphorylation while minimizing Ser112 effects, developed to circumvent weight gain and edema side effects of the parent compound. Telmisartan is identified as a partial PPARγ agonist that maintains Ser112 phosphorylation and avoids adipocytic differentiation of marrow mesenchymal stem cells, distinguishing it from full TZD agonists. Berberine is also documented as a fourth oral insulin sensitizer class — alongside metformin, TZDs, and inositols — in a network meta-analysis from the Shengjing Hospital network for endocrine and metabolic optimization in PCOS.

Incretin Agents and SGLT2 Inhibitors: The Highest-Growth Drug Repositioning Opportunity in PCOS

GLP-1 receptor agonists — liraglutide, exenatide, and semaglutide — represent the highest-growth drug repositioning opportunity in PCOS, with retrieved results from 2020–2022 consistently identifying these classes as superior to metformin for weight reduction and cardiovascular risk. The University of Ljubljana group documents consistent BMI reductions in treatment-naïve obese PCOS women and in prior metformin non-responders, while a Hull York Medical School (University of Hull) narrative review characterizes the mechanistic rationale for incretin use across the spectrum of PCOS metabolic phenotypes.

The combination of liraglutide plus metformin is identified as mechanistically synergistic — the biguanide addressing hepatic insulin resistance while the incretin agent addresses weight, appetite regulation, and incretin deficiency. Clinical development programs appear at an early-to-mid RCT stage based on dataset signals, with no large pivotal trial data evident. Standards bodies including EMA and FDA have not yet issued specific PCOS indications for GLP-1 receptor agonists, reflecting the investigational status of this repositioning.

SGLT2 inhibitors are documented in two retrieved records — from Clinical Hospital Dubrava in Zagreb and the RCSI Medical University of Bahrain — as offering superior weight and cardiovascular risk reduction compared to metformin. Their PCOS-specific use remains investigational, with mechanisms related to glycosuria-mediated insulin sensitization and weight loss rather than direct hormonal pathway intervention.

Androgen Pathway Modulators and GnRH Axis Interventions: Downstream Consequences or Direct Targets?

Androgen receptor-related approaches in the PCOS dataset primarily appear via the anti-androgen flutamide used in combination polytherapy, and via downstream sex hormone-binding globulin (SHBG) modulation by insulin sensitizers. The flutamide-pioglitazone-metformin combination — documented in metabolomics work from Rovira i Virgili University over 30 months in young non-obese PCOS women — produced normalization of metabolic oxidation pathways and endocrine markers, representing the most intensive pharmacological combination approach in the dataset. Direct androgen receptor targeting beyond anti-androgenic combinations is not prominently represented in the retrieved records.

SHBG is documented as a transcriptional target modulated by insulin, estrogens, and metformin, with gene polymorphisms at Shengjing Hospital (China Medical University) contributing to PCOS risk. Low SHBG is described as a robust biomarker for both insulin resistance and hyperandrogenism severity. The androgen biosynthetic enzymes CYP17A1, CYP11A1, and 3β-HSD type II in theca cells are identified as primary sites of androgen overproduction and indirect targets of insulin sensitizers that reduce LH-driven stimulation.

GnRH-related findings in the dataset are primarily documented as functional characterizations rather than direct GnRH analog drug interventions. A GnRH antagonist protocol is referenced in the Asan Medical Center pioglitazone IVF trial as the stimulation backbone rather than as a primary therapeutic target. The field positions GnRH axis normalization as a downstream consequence of successful insulin sensitization, and direct GnRH receptor targeting as a stand-alone therapeutic modality is not prominently featured in current pipeline approaches based on the retrieved evidence.

Combination Strategies and Emerging Molecular Targets: White Spaces in the PCOS Pipeline

Combination approaches with a metabolic plus reproductive dual-endpoint rationale are increasingly represented in records from 2019–2022. The 40:1 MI:DCI physiological ratio formulation is identified as the scientifically grounded foundation, with adjunct combinations extending to alpha-lipoic acid, N-acetylcysteine with folic acid, and monacolin K (red yeast rice-derived statin). A University of Siena record (2013) documents that MI combined with monacolin K showed a tendency toward better hormonal, metabolic, and lipid profiles versus MI alone or metformin in insulin-resistant PCOS patients.

A retrieved record from Başkent University in Ankara (2019) reports in a rat model that PDE4 inhibitor co-administration with metformin was superior to metformin alone for weight and hormonal normalization in PCOS, signaling cAMP-elevating agents as candidate adjuncts. According to data published by ClinicalTrials.gov, the number of registered PCOS intervention studies has grown substantially in recent years, reflecting the expanding pipeline activity documented in this dataset.

Mechanistically Validated but Clinically Underdeveloped Targets

The PI3K/Akt pathway and miRNA regulators — specifically miR-133a-3p and miR-19b — in granulosa cells represent mechanistically validated but clinically underdeveloped targets. miR-133a-3p is significantly upregulated in granulosa cells from obese PCOS patients, suppressing PI3K and phospho-Akt expression and reducing GLUT4, p-GSK-3β, and p-FOXO1. miR-19b is documented as targeting IGF-1 in granulosa cells, with its inhibition promoting proliferation through cyclin D1/CDK1. No therapeutic candidates directed at these miRNA targets are described in the dataset — representing a white space for RNA-targeted or kinase inhibitor approaches.

INSL5 (insulin-like peptide 5) is identified as positively and significantly correlated with AMH in PCOS across quartiles in a Zhejiang case-control study, with AMH levels rising from 4.64 to 9.48 ng/mL across INSL5 quartiles — positioning INSL5 as a novel hormonal biomarker. The SAA1 self-amplifying insulin resistance loop in granulosa cells, established by two 2021–2022 papers from Shanghai Jiao Tong University’s Renji Hospital, represents a very early-stage target with potential for IP development given the absence of any patent filing or drug candidate in the retrieved dataset.

The inositol formulation optimization opportunity is also commercially significant: retrieved results document both clinical efficacy and dose-dependent safety concerns, suggesting that proprietary fixed-dose MI:DCI ratio products with defined pharmacokinetic profiles could achieve meaningful differentiation in the nutraceutical, medical food, and pharmaceutical market — particularly if supported by multicenter RCT live birth rate data currently absent in the retrieved dataset. The Italian academic cluster (Universities of Catania, Pisa, Siena, Modena, and University of Piemonte Orientale) represents the most heavily engaged research group in this formulation science space, with commercial involvement from Lo.Li. Pharma (Rome) and Laborest.